Physician profile
Anthony R Deboni
NPI 1023106887
$17,325.01
in general payments reported to CMS, 2019-2025
18 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 86% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $288 · 2021: $884 · 2022: $507 · 2023: $1,393 · 2024: $1,521 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855 · Long Term Medical Supply Or Device Loan: $1,303 · Travel and Lodging: $11.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.91 |
| Long Term Medical Supply Or Device Loan | $1,303.20 |
| Travel and Lodging | $11.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,786.28 | 2019-2022 | |
| Abbvie INC. | $2,863.29 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Integra Lifesciences Corporation | $1,372.30 | 2025 | Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template |
| Merz North America, INC. | $999.92 | 2019-2024 | Xeomin |
| Mentor Worldwide LLC | $412.87 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Tela Bio, INC. | $331.07 | 2019-2024 | Ovitex 2s |
| Musculoskeletal Transplant Foundation INC. | $168.95 | 2019-2024 | |
| Motiva USA, LLC | $149.81 | 2025 | |
| Medtronic, INC. | $55.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $53.60 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $24.29 | 2021 | |
| Galderma Laboratories, L.P. | $22.26 | 2021 | |
| Sanara Medtech INC. | $21.33 | 2024 | Celleraterx |
| Coopersurgical, INC. | $21.23 | 2021 | |
| Kerecis Limited | $15.57 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $14.84 | 2019 | |
| Z-Medica, LLC | $12.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$165,006.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Deboni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.